Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint.

Many have observed poor correlations between serum prostate-specific antigen (PSA) and tumor volume, and this noise undoubtedly reduces the diagnostic specificity of PSA. To explore this phenomenon, we addressed the problem from a theoretical viewpoint. Specifically, we used a compartmental model and first-order kinetics to develop the mathematics necessary to relate serum PSA to tumor volume. We found that the resulting model fit well the observed kinetic data of PSA measured after biopsy or prostatectomy. The model also predicted a linear relationship between PSA and the sum of volumes of benign and malignant tissues, but the coefficients for this linear equation are more complex than previously thought. They reflect not only how much PSA may be present in each tissue but also 3 rate parameters and the volume of serum. Much of the noise in the linkage between PSA and tumor volume is due to individual patient differences in the 3 rate parameters and in serum volume. Our model predicts that without ways to directly measure the several involved rate parameters, we will not be able to accurately predict tumor volume from PSA. Nevertheless, surrogates for the missing parameters may exist and could lead to statistical models that could improve the prediction of tumor volume.

[1]  G. Thomas Calculus and Analytic Geometry , 1953 .

[2]  Brian W. Kernighan,et al.  The C Programming Language , 1978 .

[3]  M. Coptcoat,et al.  The release of free prostate specific antigen into the circulation during transurethral resection of the prostate: kinetics and interaction with serum protease inhibitors. , 1998, British journal of urology.

[4]  D. Chan,et al.  Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. , 1992, Cancer research.

[5]  Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. , 1996, Urology.

[6]  H. Lilja,et al.  Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. , 1998, Urology.

[7]  T. Wheeler,et al.  Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. , 1994, The Journal of urology.

[8]  S. Loening,et al.  Elimination of Serum Free and Total Prostate-Specific Antigen after Radical Retropubic Prostatectomy , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[9]  S. Loening,et al.  ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. , 2000, Urology.

[10]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[11]  W. Catalona,et al.  Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. , 1992, The Journal of urology.

[12]  A. Partin,et al.  Clearance rate of serum‐free and total PSA following radical retropubic prostatectomy , 1996, The Prostate. Supplement.

[13]  A. Semjonow,et al.  Half-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment? , 1992, European urology.

[14]  M. Dauge,et al.  Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy , 1995, The Prostate.

[15]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[16]  L. Boccon‐Gibod,et al.  Clearance of Free and Total Serum PSA after Prostatic Surgery , 1998, European Urology.

[17]  G. Andriole Serum prostate-specific antigen: the most useful tumor marker. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Humphrey,et al.  Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. , 1996, The Journal of urology.

[19]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[20]  J. Pontes,et al.  Prognostic implications of disappearance rate of biologic markers following radical prostatectomy. , 1990, Urology.

[21]  A Grünert,et al.  Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy--a critical assessment. , 1999, Urology.